An investigational new heart failure drug could be poised to change the face of cardiology based on Hot Line results presented today at ESC Congress 2014.
Findings from the PARADIGM-HF trial, published simultaneously in the New England Journal of Medicine, “are extraordinarily powerful and compelling; they are destined to change the management of patients with chronic heart failure for years to come,” said Milton Packer, MD, co-primary author of the study from University of Texas Southwestern Medical Center, in Dallas, Texas USA.
“This really is an astonishing result and a real breakthrough for patients with heart failure,” added John McMurray, MD, the other co-primary author, from the University of Glasgow, UK.
The new agent, an angiotensin receptor-neprilysin inhibitor (ARNI) known as LCZ696, has already been granted Fast Track status by the United States Food and Drug Administration (FDA) – a designation which can expedite the review of new medicines intended to treat serious or life-threatening conditions. Fast Track designation also allows for rolling submission in the US, which Novartis said it expects to complete by the end of 2014. The company said it aims to file in Europe in early 2015.
“To say that we are excited is an understatement. We are absolutely thrilled,” said Dr. Packer.
“Given the survival advantage of LCZ696 over currently available drugs, once this drug becomes available, it would be difficult to understand why physicians would continue to use traditional angiotensin converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) for the treatment of heart failure.”
The Latest on: Heart failure
via Google News
The Latest on: Heart failure
- Aspirin use linked with increased risk of heart failure: Studyon November 28, 2021 at 10:36 am
Other than factors such as smoking obesity high blood pressure high cholesterol diabetes and cardiovascular disease taking aspirin is associated with a 26 ...
- How an NBA player's genetic heart disease led to advocacy for hypertrophic cardiomyopathyon November 25, 2021 at 2:07 am
Jared Butler is playing in the NBA after being diagnosed while in college. Hypertrophic Cardiomyopathy Awareness A healthy athlete all his life, Jared Butler entered his college basketball physical ...
- Heart Failure Software Market Size, Share 2021 Industry Growing Rapidly with Recent Demand, Trends, Development, Revenue and Forecast to 2028on November 24, 2021 at 10:36 am
The Heart Failure Market Size Share Growth Industry Trends and Forecast 2028 Study has been added to DBMR database The study covers in depth overview description about the Product Industry Scope and ...
- Common painkiller increases risk of heart failure in certain people, docs warnon November 24, 2021 at 2:38 am
A COMMON painkiller can increase the risk of heart failure in certain people, doctors have warned. Aspirin has been linked to a 26 per cent rise in heart issues in those with at least one ...
- Can going to bed at 10 p.m. reduce heart disease risk?on November 22, 2021 at 4:02 am
What's important is consistency: going to sleep at the same time every day, getting up at the same time every day, eating meals at the same time every day.
- The Best Foods To Eat If You Have Heart Disease, Say Dietitianson November 21, 2021 at 7:02 am
If you struggle with cardiovascular issues, these are the best foods for people with heart disease, according to registered dietitians.
- Some Smokers May Not Know They Have Heart Disease Until It Kills Themon November 18, 2021 at 11:28 am
Smoking has long been linked to an increased risk of cardiovascular disease, but a new study suggests that many smokers don’t realize they’re personally at risk until they have a heart attack or ...
- Heart Disease Therapies Pack a Punch with Promising Study Resultson November 16, 2021 at 11:45 am
Heart-Disease-Therapies-Pack-a-Punch-with-Promising-Study-Results-BioSpace-11-16-21.jpeg Three companies have posted major developments in the field of heart disease therapy. AstraZeneca and Moderna ...
- Stem cell therapy for heart failure reduced major CV events and death, not hospitalizationon November 15, 2021 at 7:08 am
Stem cell therapy helped to reduce the number of heart attacks, strokes and death among people with chronic, high-risk, NYHA class II or III heart failure with reduced ejection fraction (HFrEF), ...
via Bing News